Learn more about whether Open Text Corporation or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock ...

In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

The Dow Jones Industrial Average moved off lows with the other major stock indexes in the stock market today on "quadruple ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Analysts may not have crystal balls, but they’re pretty bullish on Vertex’s 2028 outlook, despite its rocky stock performance ...

Data management has been changing rapidly in the era of generative and agentic AI, with even more change from the vendors ...

How GLP-1 drugs, regulatory concerns, and more factors are shaping the sector. Plus, 3 undervalued healthcare stocks.

Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) ("Skyharbour" or the "Company"), is pleased to announce that its partner company ...

Airbnb defied the broader market downturn, inching up 0.12% while the S&P 500, Dow, and Nasdaq all dipped into the red. The ...